Efficacy and safety of reduced dose of Dabigatran, Rivaroxaban and Apixaban in patients with atrial fibrillation for stroke prevention.

Trial Profile

Efficacy and safety of reduced dose of Dabigatran, Rivaroxaban and Apixaban in patients with atrial fibrillation for stroke prevention.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Apixaban; Dabigatran etexilate
  • Indications Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Sep 2017 New trial record
    • 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top